Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Markers in breast cancer: does CEA add to the detection by CA 15.3?

Literature DB >> 3167234

Markers in breast cancer: does CEA add to the detection by CA 15.3?

J C Delarue¹, H Mouriesse, F Dubois, S Friedman, F May-Levin.

Abstract

211 patients with various stages of breast cancer were studied by both the CA 15.3 and CEA markers to assess whether the latter may increase the screening sensitivity of the former. While both markers were equally specific, CA 15.3 was seen to be much more sensitive than CEA (p less than 0.0001). Also, the addition of the CEA did not add appreciably (7%) to positive detection by CA 15.3. There appears to be no advantage to including CEA in a marker panel to follow the course of breast carcinoma.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1988 PMID： 3167234 DOI： 10.1007/bf01807287

Source DB: PubMed Journal: Breast Cancer Res Treat ISSN： 0167-6806 Impact factor: 4.872

9 in total

1. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.

Authors: D F Hayes; V R Zurawski; D W Kufe
Journal: J Clin Oncol Date: 1986-10 Impact factor: 44.544

2. CA 15.3: early results of a new breast cancer marker.

Authors: R Colomer; L A Sole; M Navarro; G Encabo; A Ruibal; L Salvador
Journal: Anticancer Res Date: 1986 Jul-Aug Impact factor: 2.480

3. Evaluation of CA15/3 serum levels in breast cancer patients.

Authors: M Gion; R Mione; R Dittadi; S Fasan; A Pallini; G Bruscagnin
Journal: J Nucl Med Allied Sci Date: 1986 Jan-Mar

4. Prognostic significance of CEA in breast cancer: a statistical study.

Authors: M De Jong-Bakker; A A Hart; J P Persijn; F J Cleton
Journal: Eur J Cancer Clin Oncol Date: 1981-12

5. Biological markers for breast carcinoma.

Authors: T P Waalkes; J P Enterline; J H Shaper; M D Abeloff; D S Ettinger
Journal: Cancer Date: 1984-02-01 Impact factor: 6.860

6. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.

Authors: D Kufe; G Inghirami; M Abe; D Hayes; H Justi-Wheeler; J Schlom
Journal: Hybridoma Date: 1984

Review 7. Carcinoembryonic antigen in breast cancer. Clinical review.

Authors: D B Beard; C M Haskell
Journal: Am J Med Date: 1986-02 Impact factor: 4.965

8. Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer.

Authors: J Schlom; J Greiner; P H Hand; D Colcher; G Inghirami; M Weeks; S Pestka; P B Fisher; P Noguchi; D Kufe
Journal: Cancer Date: 1984-12-01 Impact factor: 6.860

9. Value of CA 15:3 in the follow-up of breast cancer patients.

Authors: D M Pons-Anicet; B P Krebs; R Mira; M Namer
Journal: Br J Cancer Date: 1987-05 Impact factor: 7.640

9 in total

6 in total

1. Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer.

Authors: M B Garcia; M A Blankenstein; E van der Wall; J W Nortier; J H Schornagel; J H Thijssen
Journal: Breast Cancer Res Treat Date: 1990-12 Impact factor: 4.872

2. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.

Authors: E Vizcarra; A Lluch; R Cibrián; F Jarque; V Alberola; V Belloch; J García-Conde
Journal: Breast Cancer Res Treat Date: 1996 Impact factor: 4.872